Biochemistry & Molecular Biology Journal Open Access

  • ISSN: 2471-8084
  • Journal h-index: 12
  • Journal CiteScore: 2.55
  • Journal Impact Factor: 1.74
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Reach us +32 25889658


Evaluation of Adenosine deaminase (ADA) level in serum of patients with prostate cancer

Reza Saghiri*

Aim: Prostate cancer is a developing cancer in prostate gland. It is one of the common cancers among men. This cancer usually develops slowly but sometimes it is metastatic form. Screening of prostate cancer is done by measuring the PSA level, but it sometimes leads to over diagnosis in some cases. Therefore, finding another factor except PSA, for screening the cancer seems necessary. Elevation in the level of ADA is observed in some diseases like cancers. It is considered that measuring ADA level beside PSA level could be a helpful factor for screening prostate cancer.

Methods: In this study, blood sample were collected from 40 patients and 40 control participants matched for age. PSA, free PSA and ADA levels were compared in the serum of both groups. PSA assessment was based on sandwich ELISA although ADA level was measured by colorimetric methods. SPSS software was used for analyzing data.

Results: According to obtained data from patient and control groups the mean of PSA level was 23.9 ± 11.96 ng/ml and 1.33 ± 0.61 ng/ml, respectively which showed a significant increase in patients (P<0.05). ADA level was 30.99 ± 0.99 U/L and 9.8 ± 0.8 U/L in patient and control groups. It is significantly higher in patients than controls (P<0.05).

Conclusion: The study results showed a significant elevation in PSA and ADA levels in prostate cancer patients compared with control group. Therefore, serum ADA and PSA levels might be useful indexes in screening and monitoring of prostate cancer.

Published Date: 2023-10-30; Received Date: 2023-03-01